Last updated: September 9, 2026
Ocriplasmin, marketed as Jetrea, is a recombinant truncated human plasmin used by intravitreal injection to treat symptomatic vitreomacular adhesion. The product won FDA approval in 2012 but generated limited commercial adoption because of narrow eligibility, variable clinical benefit, administration by retinal specialists, safety concerns, and competition from vitrectomy. Its financial trajectory moved from an initial launch opportunity to declining, non-core revenue. The European marketing authorization was withdrawn, and commercial activity has contracted substantially. Oxurion, formerly ThromboGenics, ultimately failed to build a sustainable business around Jetrea and entered bankruptcy proceedings in 2023.
What is ocriplasmin and which market does it address?
Ocriplasmin is a 27.7-kDa recombinant proteolytic enzyme derived from human plasmin. It is administered as a single 0.125 mg intravitreal injection. Its approved use is the treatment of symptomatic vitreomacular adhesion in adults, including cases associated with a macular hole of 400 micrometers or less in the United States.[1]
The target market is a subset of patients with vitreomacular adhesion or vitreomacular traction. The condition is common in older adults, but only a minority of patients meet the clinical and anatomical profile for pharmacologic vitreolysis.
The commercial opportunity was constrained by four factors:
- Many patients are monitored without intervention.
- Patients with advanced traction or larger macular holes often proceed directly to vitrectomy.
- Ocriplasmin has inconsistent efficacy across patient subgroups.
- Intravitreal administration requires retinal-specialist infrastructure.
The product was designed to replace or delay surgery in selected patients, not to address the entire vitreomacular traction market.
When did ocriplasmin receive FDA approval?
The FDA approved Jetrea on October 17, 2012, under New Drug Application 204275.[1] The approval was based primarily on the MIVI-TRUST phase 3 program, which evaluated pharmacologic release of vitreomacular adhesion.
Key FDA milestones
| Milestone |
Date |
Commercial significance |
| FDA approval of Jetrea |
October 17, 2012 |
Established the first approved pharmacologic vitreolysis product in the U.S. |
| U.S. commercial launch |
2013 |
Initiated specialist-driven market development |
| European Union authorization |
2013 |
Created a second major regulatory market |
| U.S. postmarketing safety monitoring |
Ongoing after approval |
Increased physician scrutiny of retinal and visual adverse events |
| EU marketing authorization withdrawal |
2018 |
Removed the product from routine EU commercial distribution |
| Oxurion bankruptcy proceedings |
2023 |
Ended the original developer’s independent commercial model |
The European Medicines Agency withdrew the Jetrea marketing authorization at the company’s request in 2018. The stated basis was commercial rather than a broad finding that the product was unsafe or ineffective.[2]
How did ocriplasmin sales perform after launch?
Ocriplasmin sales peaked well below the commercial expectations associated with a first-in-class ophthalmic biologic. The product’s revenue curve reflected rapid physician adoption in selected retinal centers followed by slower utilization, limited repeat use, and shrinking commercial investment.
ThromboGenics’ public filings reported Jetrea revenue in the tens of millions of euros rather than at the scale required to support a large specialty-pharmaceutical organization. Revenue declined as the company reduced commercial spending, licensing arrangements changed, and physicians became more selective in patient treatment.[3-6]
Estimated commercial trajectory
| Period |
Market position |
Financial direction |
| 2013-2014 |
Initial U.S. launch and specialty adoption |
Revenue increased from a low base |
| 2015-2016 |
Broader physician experience with efficacy and tolerability |
Growth slowed; commercial expectations were reduced |
| 2017-2018 |
Rights and commercialization structure changed |
Revenue declined and became less strategic |
| 2019-2021 |
Smaller commercial footprint and distributor-led activity |
Low and declining product revenue |
| 2022-2023 |
Jetrea no longer supported a viable corporate platform |
Product contribution was immaterial relative to financing needs |
Public reporting indicates that Jetrea sales never reached blockbuster scale. Peak annual revenue was approximately in the tens-of-millions-of-euros range, not hundreds of millions. The product’s economics were weakened by the need for specialist sales forces, operating-room alternatives, limited treatment frequency, and the cost of maintaining global regulatory and supply infrastructure.[3-6]
Why did ocriplasmin underperform commercially?
The central commercial problem was a mismatch between the addressable population and the number of patients who achieved a sufficiently valuable clinical outcome.
The MIVI-TRUST studies showed statistically significant improvement in vitreomacular adhesion release, but the overall response rate was modest. Benefit was higher in selected subgroups, including patients without epiretinal membrane, patients with smaller focal adhesions, and patients with phakic lenses. These selection criteria reduced the practical market size.[1]
Main demand constraints
Limited eligible population
The approved indication was narrower than the broader population with vitreomacular traction. Retinal specialists could not use ocriplasmin as a general treatment for all symptomatic cases.
Inconsistent efficacy
Ocriplasmin did not reliably release traction in every treated eye. Physicians often considered observation or vitrectomy more predictable for patients with substantial traction or structural damage.
Safety and tolerability concerns
The label includes warnings and precautions relating to visual disturbances, retinal tears or detachments, reduced visual acuity, lens-related events, dyschromatopsia, and electroretinographic changes.[1] These events did not eliminate use, but they increased treatment selectivity.
One-time treatment economics
Unlike chronic retinal biologics such as ranibizumab or aflibercept, ocriplasmin generally generated one treatment event per eligible eye. That limited revenue per patient and reduced recurring demand.
Strong procedural substitute
Vitrectomy has higher upfront procedural burden but can offer a more definitive mechanical solution. In cases where surgery was already likely, the value proposition for ocriplasmin was weak.
What is the FDA regulatory status of Jetrea?
Jetrea received full FDA approval for its labeled indication. The product was not approved under an accelerated approval pathway, and it is not a biosimilar or interchangeable biologic.
The FDA-approved label remains the relevant regulatory basis for use, but regulatory approval does not guarantee current commercial availability. U.S. distribution and supply have been substantially more limited than during the original launch period. Commercial status should be distinguished from withdrawal of an NDA: a product may remain approved in FDA records while being discontinued or difficult to obtain commercially.
The product is supplied as a single-use vial that requires reconstitution and intravitreal administration. This creates handling and wastage considerations for treatment centers.
What is the Orange Book status of ocriplasmin?
Jetrea is listed in FDA drug-product records under NDA 204275. The relevant intellectual-property question is less significant commercially than it was at launch because the product has experienced low demand and reduced commercial support.
The Orange Book should be evaluated for current patent listings rather than relying on historical patent assumptions. Ocriplasmin’s core composition and treatment patents were filed well before approval, so the effective U.S. exclusivity period has largely elapsed or is no longer the primary market barrier. The principal barriers now are manufacturing, regulatory compliance, physician adoption, and distribution.
A generic or follow-on entrant would still need to address:
- Recombinant protein production and purification
- Sterile ophthalmic manufacturing
- Stability and cold-chain requirements
- Intravitreal delivery quality controls
- Clinical and regulatory requirements for a complex biologic
- Limited market size and uncertain commercial return
What patents protect ocriplasmin?
Ocriplasmin was protected by a group of patent families covering microplasmin, vitreoretinal disorders, pharmacologic vitreolysis, and ophthalmic use. The original developer, ThromboGenics, relied on composition, treatment-method, and formulation-related rights.
Principal patent categories
| Patent category |
Protected subject matter |
Commercial relevance |
| Composition patents |
Recombinant microplasmin or ocriplasmin molecules |
Core product protection |
| Method-of-use patents |
Treatment of vitreomacular adhesion and related retinal conditions |
Limited use protection around the approved indication |
| Formulation patents |
Stabilized, sterile ophthalmic preparations |
Manufacturing and product-quality protection |
| Manufacturing patents |
Recombinant expression, purification, and processing |
Potential barrier to follow-on manufacture |
| Delivery patents |
Intravitreal administration and dosing approaches |
Narrower protection than composition claims |
The patent estate was stronger during the launch period than it is today. The main commercial risk is no longer a conventional branded-product patent cliff. It is the lack of a sufficiently large market to attract a well-capitalized generic or biosimilar developer.
Is there biosimilar risk for ocriplasmin?
Ocriplasmin is a biologic, so a follow-on developer would likely face a biologics regulatory pathway rather than a simple small-molecule ANDA pathway. The FDA’s 351(k) biosimilar pathway could be relevant, but an ocriplasmin biosimilar would still need to demonstrate analytical similarity and address clinical or pharmacologic comparability as required by the FDA.[7]
No major biosimilar competitor has established a material commercial position in ocriplasmin. The limited opportunity reflects:
- Small and declining demand
- High sterile-manufacturing requirements
- Specialist-only administration
- Low frequency of repeat dosing
- Uncertain reimbursement
- Competition from surgery rather than from another drug
A follow-on product could create price pressure if it achieved reliable supply and payer acceptance. It would not automatically create a large market.
Which companies commercialized or challenged ocriplasmin?
ThromboGenics developed ocriplasmin and commercialized Jetrea through arrangements involving Novartis and Alcon. Commercial rights and responsibilities changed over time as the product underperformed expectations.
The key commercial participants were:
| Company |
Role |
| ThromboGenics, later Oxurion |
Developer, patent holder, and original strategic sponsor |
| Novartis |
Development and commercialization partner in the original global structure |
| Alcon |
Ophthalmology commercial organization associated with U.S. commercialization |
| Inceptua |
Later commercial and distribution partner for selected markets |
There was no major successful generic or biosimilar challenge comparable to the patent challenges seen in large chronic ophthalmology franchises. The primary competitive pressure came from vitrectomy, observation, and physician reluctance to use ocriplasmin in marginal cases.
What patent litigation and settlement agreements affected Jetrea?
Ocriplasmin did not produce a major, widely reported patent-litigation campaign involving multiple generic challengers. Publicly visible commercial history is dominated by licensing, rights transfers, marketing retrenchment, and corporate restructuring rather than Paragraph IV litigation.
No material Paragraph IV challenge became a central driver of Jetrea’s market decline. The product’s weakness was demand-side and commercial, not the result of a successful generic invalidating or circumventing the core patent estate.
How did licensing deals affect ocriplasmin revenue?
The original partnership structure gave ThromboGenics access to global ophthalmology commercialization capabilities but also reduced direct control over sales execution and economics. As revenue disappointed, rights were reorganized and commercial responsibilities moved between the originator and partners.
This structure created several financial effects:
- Shared economics reduced the originator’s retained product revenue.
- Commercial partners had to justify sales-force investment against a narrow indication.
- Rights returns increased the originator’s operational burden.
- Later distributor arrangements reduced fixed costs but also limited market-building activity.
- Revenue became less predictable as supply and geographic coverage contracted.
The licensing model was rational for a first-in-class retina product at launch. It became less attractive after the addressable market proved smaller than anticipated.
What generic launch risks exist for ocriplasmin?
A generic or biosimilar launch would face lower legal risk than a launch during the original patent term, but the commercial case remains weak.
Potential launch scenarios
| Scenario |
Probability profile |
Market effect |
| Continued limited branded supply |
Most commercially plausible |
Stable but small niche revenue |
| One follow-on biologic enters |
Possible if manufacturing economics improve |
Price erosion and reduced branded share |
| Multiple competitors enter |
Unlikely given market size |
Significant price compression |
| Product becomes unavailable in additional markets |
Material risk |
Physicians shift to surgery or observation |
| Reimbursement or clinical-guideline restriction |
Possible |
Further reduction in utilization |
For a follow-on entrant, manufacturing scale and reliable supply may matter more than patent clearance. The product requires sterile biologic production, and the total market may not support the development and launch costs.
How does ocriplasmin compare with competing retinal drugs?
Ocriplasmin has a materially weaker commercial profile than chronic anti-VEGF drugs.
| Attribute |
Ocriplasmin |
Aflibercept or ranibizumab |
| Primary use |
Vitreomacular adhesion |
Retinal vascular and neovascular diseases |
| Administration |
Usually one intravitreal injection per eligible eye |
Repeated injections |
| Revenue model |
Episodic |
Recurring |
| Market size |
Narrow |
Large |
| Main competitor |
Vitrectomy and observation |
Other anti-VEGF agents |
| Physician value proposition |
Avoid or delay surgery in selected patients |
Preserve or improve vision through chronic treatment |
| Biosimilar pressure |
Limited |
Increasing and commercially significant |
| Current commercial strength |
Low |
High relative to ocriplasmin |
Ocriplasmin’s one-time dosing was clinically attractive but financially limiting. Chronic retinal drugs generate repeated treatment revenue and support larger specialist sales organizations.
What is the financial outlook for ocriplasmin?
The financial outlook is defensive rather than growth-oriented. Jetrea can retain value as a niche product if it remains available to carefully selected patients, but it is unlikely to regain its original commercial trajectory without new evidence, broader adoption, or a materially improved formulation.
Oxurion’s bankruptcy in 2023 confirms that Jetrea revenue was insufficient to fund the company’s broader development program and corporate structure.[8] The product’s remaining value is more likely to arise from:
- Sale or licensing of residual commercial rights
- Regional distribution agreements
- Supply continuity in selected markets
- Strategic use in specialist centers
- Potential manufacturing transfer to a lower-cost operator
The product has limited value as a platform asset. Its value is primarily as a niche revenue stream with established regulatory history.
Key Takeaways
- Ocriplasmin received FDA approval in 2012 as Jetrea for symptomatic vitreomacular adhesion.
- Its addressable market was narrow and its efficacy was strongest in carefully selected patients.
- Sales remained in the tens-of-millions-of-euros range at peak and declined thereafter.
- Physician adoption was limited by variable efficacy, safety concerns, treatment-center logistics, and vitrectomy competition.
- The EU marketing authorization was withdrawn in 2018 for commercial reasons.
- No major Paragraph IV challenge or biosimilar competitor drove the product’s decline.
- Patent protection is less important today than manufacturing cost, supply continuity, and market size.
- Jetrea revenue did not support Oxurion’s long-term corporate strategy, which ended in bankruptcy proceedings in 2023.
- The remaining opportunity is a small specialty market, not a conventional branded-biologic growth asset.
FAQs
Is ocriplasmin still commercially available?
Availability is limited and varies by market. FDA approval and commercial distribution are separate issues. The product has experienced substantial commercial retrenchment since launch.
Can ocriplasmin replace vitrectomy?
Ocriplasmin can release vitreomacular adhesion in selected patients, but it does not replace vitrectomy for all cases. Surgery remains the more predictable option for many patients with advanced traction or structural retinal damage.
Is Jetrea a biosimilar?
No. Jetrea is the original branded biologic product containing ocriplasmin. A future follow-on product would require a separate regulatory application.
Did ocriplasmin become a blockbuster drug?
No. Ocriplasmin generated specialty-product revenue but did not approach blockbuster scale. Its peak commercial performance was constrained by the narrow indication and one-time dosing model.
What is the largest threat to ocriplasmin revenue?
The largest threat is continued clinical substitution by observation and vitrectomy, combined with reduced product availability. Conventional patent expiry is less important than declining physician use and limited commercial infrastructure.
References
-
U.S. Food and Drug Administration. (2012). Jetrea (ocriplasmin) injection: Prescribing information. FDA.
-
European Medicines Agency. (2018). Jetrea: Withdrawal of the marketing authorisation in the European Union. EMA.
-
ThromboGenics NV. (2014). Annual report 2013. ThromboGenics.
-
ThromboGenics NV. (2015). Annual report 2014. ThromboGenics.
-
ThromboGenics NV. (2017). Annual report 2016. ThromboGenics.
-
Oxurion NV. (2021). Annual report 2020. Oxurion.
-
U.S. Food and Drug Administration. (2023). Biosimilar and interchangeable biologic product development, review, and approval. FDA.
-
Oxurion NV. (2023). Corporate announcements regarding bankruptcy proceedings and business operations. Oxurion.
